Mesenchymal stem cells (MSCs) have huge therapeutic potential for numerous unmet medical needs.
This has already been demonstrated and is widely documented.
Cynata’s unique Cymerus™ technology addresses many of the complexities and challenges of manufacturing these cells at commercial scale.
Using leading edge science from the world’s pre-eminent stem cell center we have a starting material with unlimited expansion potential, which means that we and our commercial partners can source all the cells we will ever need from a single blood donation.
This in turn means we can manufacture robust and consistent MSCs in an economically viable process – all under Good Manufacturing Practice (GMP) requirements.
Learn more about Cymerus™ here, and how Cynata is set to accelerate the commercialization of MSC therapies worldwide.